Related Experiment Video
Updated: Oct 25, 2025
05:42
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
2.9K
Colon carcinoma presenting as ovarian metastasis
Paul Geraeds Kemps1,2, Mijke Bol3, Ernst Johan Abraham Steller4
1Department of Gynecology and Obstetrics, Haga Hospital, The Hague, The Netherlands.
Radiology Case Reports
|August 9, 2021
Summary
Ovarian metastasis from colon cancer can occur in premenopausal women with adnexal masses. Identifying KRAS mutations in both primary colon and ovarian tumors highlights its role in metastatic disease.
Area of Science:
- Gynecologic Oncology
- Gastroenterology
- Oncology
Background:
- Adnexal masses are common gynecologic findings, frequently benign in premenopausal women.
- Distinguishing benign masses from malignancy is crucial for appropriate patient management.
Observation:
- A premenopausal woman presented with an adnexal mass initially presumed benign.
- The mass was diagnosed as an ovarian metastasis originating from colon cancer.
Findings:
- The same KRAS mutation was identified in both liver and ovarian metastases.
- KRAS mutations are present in over 50% of colorectal cancers with ovarian metastases.
- Mutated KRAS appears to be a key driver in KRAS-mutated colorectal cancer with ovarian metastases.
Implications:
- This case highlights the importance of considering ovarian metastasis in patients with solid adnexal masses, even with low CA125 levels.
- KRAS inhibitors may represent a future therapeutic strategy for colorectal cancer patients with ovarian metastases.
